Rationale, design, and baseline characteristics of the prospective randomized evaluation of the vascular effects of norvasc trial (prevent)

American Journal of Cardiology

Volumn 80, Issue 8, 1997, Pages 1087-1090

  Byington, Robert P ^a   Miller, Michael E ^a   Herrington, David ^a   Riley, Ward ^a   Pitt, Bertram ^a   Furberg, Curt D ^a   Hunninghake, Donald B ^a   Mancini, G B John ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B SCAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; AMLODIPINE; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0030704711     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00611-5     Document Type: Article

References (8)

1. Tulenko TN, Stepp DW, Chen M, Moisey D, Laury-Kleintop L, Mason RP. Actions of the charged dihydropyridine amlodipine in a cell culture model of dietary atherosclerosis. J Cardiovasc Pharmacol 1995;26(suppl A)S11-S17.
2. Kramsch DM, Sharma RC. Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J Hum Hypertens 1995;9(suppl 1)S3-S9.
3. Principal Investigators of CASS and Their Associates. The National Heart, Lung, and Blood Institute Coronary Artery Surgery Study. Circulation 1981; 63(suppl I):I-1-I-15.
4. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-1687.
5. Crouse JR, Byington RP, Bond MG, Espeland ME, Craven TE, Sprinkle JW, McGovern M, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) a clinical trial with atherosclerosis outcome. Am J Cardiol 1995;75:455-459.
6. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, on Behalf of the INTACT Group Investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335: 1109-1113.
7. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G Lemarbre L, Reitman M, Joyal M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;821:940-1953.
8. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375.